Nektar Therapeutics (Nasdaq: NKTR) reported upbeat results from a PIVOT-02 Phase 1/2 study of Opdivo with NKTR-214 sending the stock price soaring $4.60 to close at $37.10.
Nektar Therapeutics reports upbeat study results
November 13, 2017 at 16:54 PM EST
